Abstract:Immune checkpoint proteins have become recent research hotspots for their vital role in maintaining peripheral immune tolerance and suppressing immune response function in a wide range of tumors. Therefore, investigating the immunomodulatory functions of immune checkpoints and their therapeutic potential for clinical use is of paramount importance. The immune checkpoint blockade (ICB) is an important component of cancer immunotherapy, as it targets inhibitory immune signaling transduction with antagonistic antibodies to restore the host immune response. Anti-programmed cell death-1 (PD-1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies are two main types of widely used ICBs that drastically improve the survival and prognosis of many patients with cancer. Nevertheless, the response rate of most cancer types remains relatively low due to the drug resistance of ICBs, which calls for an in-depth exploration to improve their efficacy. Accumulating evidence suggests that immune checkpoint proteins are glycosylated in forms of N-glycosylation, core fucosylation, or sialylation, which affect multiple biological functions of proteins such as protein biosynthesis, stability, and interaction. In this review, we give a brief introduction to several immune checkpoints and summarize primary molecular mechanisms that modulate protein stability and immunosuppressive function. In addition, newly developed methods targeting glycosylation on immune checkpoints for detection used to stratify patients, as well as small-molecule agents disrupting receptor-ligand interactions to circumvent drug resistance of traditional ICBs, in order to increase the clinical efficacy of immunotherapy strategies of patients with cancer, are also included to provide new insights into scientific research and clinical treatments.

The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Interaction of Molecular Alterations with Immune Response in Melanoma

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Targeted glycan degradation potentiates the anticancer immune response in vivo

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Immune Checkpoints in Cancers: From Signaling to the Clinic

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications

Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2

Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Recent advances in sialic acid-based active targeting chemoimmunotherapy promoting tumor shedding: a systematic review

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches